Dynamic monitoring of cardio-specific markers and markers of thyroid gland function in cancer patients - A pilot study

Anticancer Research

Volumn 27, Issue 4 A, 2007, Pages 1883-1886

  Holubec Jr , Lubos ^a,b   Topolcan, O ^a   Finek, J ^a   Salvet, J ^a   Svoboda, T ^a   Svobodova, S ^a   Mrazkova, P ^a   Ludvikova, M ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Medical Faculty Pilsen ^*  (Czech Republic)

Author keywords

Cardiospecific enzymes; Chemotherapy; Radiotherapy; Side effects; Thyroid function markers

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; FLUOROURACIL; FOLINIC ACID; THYROTROPIN; TROPONIN I;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL FEATURE; COLORECTAL CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; FREE THYROXINE INDEX; HEART FAILURE; HEART MUSCLE ISCHEMIA; HUMAN; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; THYROID FUNCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLUOROURACIL; HEART; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; NATRIURETIC PEPTIDE, BRAIN; PALLIATIVE CARE; PILOT PROJECTS; THYROID GLAND; THYROTROPIN; THYROXINE; TROPONIN I;

EID: 34250775910     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Rubin P: Basic Concepts of cancer chemotherapy and principles of medical oncology. In: Clinical Oncology: A Multidisciplinary Approach for Physicians and Students. W.B. Saunders Company, US, pp. 146-160, 2001.
2. Topolcan O, Holubec L Jr, Finek J, Stieber P, Holdenrieder S, Lamerz R, Holubec Sen L, Svobodova S, Visokai V and Lipska L: Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Res 25(3A): 1831-1833, 2005.
3. Chang AE and Skibber JM: Colon, rectal, and anal cancer management. In: Oncology. An Evidence-based Approach. Springer, US, pp. 1753-1767, 2006.
4. Dokainish H, Zoghbi WA, Ambriz E, Lakkis NM, Quinones MA and Nagueh SF: Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure. Am J Cardiol 97(3): 400-403, 2006.
5. Chapelle JP: Cardiac troponin I and troponin T: recent players in the field of myocardial markers. Clin Chem Lab Med 37: 11-20, 1999.
6. De Vita VT, Hellman S and Rosenberg AS: Cardiac toxicity. In: Cancer: Principles and Practice of Oncology, 7th ed. Lippincott Williams & Wilkins Publishers, Baltimore, pp. 2545-2533, 2005.
7. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, Sakelariou D, Koufos C and Stamatelos G: Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy - a survey of 427 patients. Med Sci Monit 8(6): 151-157, 2002.
8. Meydan N, Kundak I, Yavuzsen T, Oztop I, Barutca S, Yilmaz U and Alakavuklar MN: Cardiotoxicity of de Gramont's regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol 35(5): 265-270, 2005.
9. Shoemaker LK, Arora U and Rocha Lima CM: 5-Fluorouracil-induced coronary vasospasm. Cancer Kontrol 11(1): 46-49, 2004.
10. Chang AE and Gharib MI: Cardiac complications. In: Oncology. An Evidence-based Approach. Springer, US, pp. 1411-1418, 2006.
11. Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U and Schmiegel W: 5-Fluorouracil induces arterial vasocontractions. Ann Oncol 15(4): 661-664, 2004.
12. Limanova Z and Jiskra J: Thyroid diseases in oncological patients. Cas Lek Cesk 144(8): 524-528, 2005.
13. Jiskra J, Limanova Z and Barmanova J: Autoimmune thyroid disease in women with breast cancer and colorectal cancer. Physiol Res 53: 693-702, 2004.
14. Dietz B and Van der Hem KG: Late-onset cardiotoxicity of chemotherapy and radiotherapy. Neth J Med 61(6): 228-231, 2003.